68Ga-DOTA-TATE PET/CT Imaging in NETs
A phase 3 trial of Gallium-68 DOTATATE in Neuroendocrine tumours, run by Centre de recherche du Centre hospitalier universitaire de Sherbrooke, with a status the registry has not verified recently.
Overview
68Ga-DOTA-TATE PET/CT Imaging in NETs is a phase 3 interventional study registered as NCT04847505 by Centre de recherche du Centre hospitalier universitaire de Sherbrooke, with 5000 participants planned, started 2020-01-01 and due to reach its primary completion in 2025-12-31. Interventions recorded: 68Ga-DOTA-TATE. Conditions recorded: Neuroendocrine Tumors.
Linked to the drug Gallium-68 DOTATATE because the registry names it among its interventions and Neuroendocrine tumours among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialStudy of Dotatate Imaging in Breast Cancer
Shares Gallium-68 DOTATATE (and Cu-64 DOTATATE) and the tag pipeline.
- TrialDual 64Cu-DOTATATE and 18F-FDG PET/CT Imaging of Patients With Neuroendocrine Neoplasms
Shares Neuroendocrine tumours and the tag pipeline.
- TrialA Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy
Shares Neuroendocrine tumours and the tag pipeline.
- TrialTelotristat With Lutathera in Neuroendocrine Tumors
Shares Neuroendocrine tumours and the tag pipeline.
- TrialA Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors
Shares Neuroendocrine tumours and the tag pipeline.
- TrialA Study of PM8002 in Combination With Chemotherapy in Patients With NEN
Shares Neuroendocrine tumours and the tag pipeline.
- TrialA Clinical Study of Lutetium[177Lu] Oxodotreotide Injection in Patients With Advanced Neuroendocrine Neoplasms
Shares Neuroendocrine tumours and the tag pipeline.
- TrialDose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Shares Neuroendocrine tumours and the tag pipeline.